Home Monitor for AA Burden Detection IIT in TWN (FF108)
The Clinical Follow-Up of the Amvia Pacemaker Family Using Atrial Anti-Tachycardia Pacing (aATP) and Home Monitoring Function in the Patients With Paroxysmal Atrial Fibrillation (PAF)
Primary Endpoint:
- Early detection rate in Atrial Arrhythmia (AA) burden
- Data transmission success rate for overall number of atrial burden collection during the monitoring period
Secondary Endpoints:
- Atrial burden occurrence at 3/6/12 months post-aATP
- Incidence of arrhythmia
- Safety: Immediate (< 24 hours), in-hospital, 3 months, 6 months and 12 months adverse events
Visão geral do estudo
Status
Descrição detalhada
This prospective observational single-arm, open-label, non-randomized, multi-center study to evaluate the impact of advanced remote monitoring technologies and features, such as the aATP function of BIOTRONIK pacemakers, in conjunction with wireless monitoring via the CardioMessenger 4G or its successors. The study population will consist of patients diagnosed with PAF or atrial flutter who will be/have been implanted with permanent pacemaker devices and CardioMessenger Smart Home Monitoring before joining the study.
Eligible patients will be enrolled through the process of informed consent in the clinical investigational sites across Taiwan with competitive enrollment.
All subjects enrolled in the study will use aATP and HM function of BIOTRONIK pacemakers. During the screen period, the subject's medical history and demographic information will be collected. The baseline data will be obtained prior to the pacing implantation. Depending on the needs of the subject, the screen and implantation procedures may be performed on the same day (within 12 weeks of baseline). Implant data will include features of aATP function, implant technique, and lead positioning. After completion of pacemaker implantation, subjects will be followed at 3, 6, and 12 months or until patient withdrawal or death. During follow-up, a determination/evaluation will be performed based on the data collection from the device system. Unscheduled visit will be arranged after investigator evaluated patient's data via HMSC and judged the clinic visit is needed.
With BIOTRONIK Home Monitoring, medical and technical data is sent from the implanted device to the CardioMessenger. This data is then forwarded to the BIOTRONIK Home Monitoring Service Center via the cellular telephone network.
Investigators who monitor subjects implanted device can review this data from the Home Monitoring Service Center website (HMSC website).
In the study, subject demographics (age, gender, height, weight, etc.) and comorbidities will be collected during the screen period. Implant procedure details and pacing parameters will be recorded. Both primary and secondary endpoints will be collected and evaluated at baseline and follow-up periods.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Chih-Chieh Yu, MD.PhD
- Número de telefone: 0972652038
- E-mail: sweetchieh@gmail.com
Estude backup de contato
- Nome: HSIAO-HAN HUANG
- Número de telefone: 0932917553
- E-mail: clrhuang8853@gmail.com
Locais de estudo
-
-
-
Taipei, Taiwan, 100
- National Taiwan University Hospita
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Adult patients ≥ 20 years of age
- Diagnosed with Paroxysmal Atrial Fibrillation (PAF) or atrial flutter who have been implanted or planned to implant with permanent pacemaker device
- The diagnosis of AF is confirmed on a 12-lead electrocardiogram (ECG) or lasting >30 seconds in single lead ECG monitor
- Implanted within 12 weeks prior to enrollment or being considered for implantation of a PPM with Home Monitoring technology
- Able to give informed consent for the participation in the trial
Exclusion Criteria:
- Patients are not able to use CardioMessenger 4G or its successors
- Life expectancy < 1 year
- Sepsis
- Long-standing Persistent Atrial Fibrillation or Permanent Atrial Fibrillation
- Pregnant or breast-feeding women
- Abnormal baseline findings considered by the investigator to indicate conditions that might affect study endpoints
- Participation in another prospective interventional clinical study within a period of 4 weeks prior to the implantation of Atrial Arrhythmia
- Present or history of drug addiction
- Any other condition that, in the investigator's judgment, might increase the risk to the patients or affect trial quality
- Patients underwent implantable cardioverter-defibrillator implantation
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Diagnosed with Paroxysmal Atrial Fibrillation (PAF) or atrial flutter
W who have been implanted or planned to implant with permanent pacemaker device
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
AA burden
Prazo: From enrollment to the end of treatment at 12-16 months (including periods of screen, treatment, and follow-ups)
|
|
From enrollment to the end of treatment at 12-16 months (including periods of screen, treatment, and follow-ups)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of arrhythmia
Prazo: From enrollment to the end of treatment at 12-16 months (including periods of screen, treatment, and follow-ups)
|
|
From enrollment to the end of treatment at 12-16 months (including periods of screen, treatment, and follow-ups)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 202602039DIPC
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .